Lilly to sell obesity drugs directly on Hims & Hers site
HIMS•Eli Lilly struck a deal allowing Hims & Hers to sell Zepbound and Foundayo directly on its platform. Self-pay prices start at $149 per month for Foundayo and $299 for Zepbound, matching LillyDirect prices.
1. Direct sales deal
Lilly said Hims & Hers will sell its obesity drugs Zepbound and Foundayo directly on the telehealth platform. Previously, patients had to leave the site and use LillyDirect to access the drugs.
2. Pricing and terms
Self-pay prices start at $149 per month for Foundayo and $299 for Zepbound, matching prices on LillyDirect. Lilly USA President Ilya Yuffa said the companies agreed that Hims & Hers will not sell compounded versions or knockoffs of Lilly’s obesity medications.
3. Market context
Hims & Hers shares rose more than 7% in premarket trading. Lilly said 40% to 45% of Zepbound sales come through self-pay channels. The deal puts Lilly on equal footing with Novo Nordisk, whose Wegovy and Ozempic have been available through Hims & Hers since March.
